MCID: DYS015
MIFTS: 49

Dysentery

Categories: Blood diseases, Gastrointestinal diseases

Aliases & Classifications for Dysentery

MalaCards integrated aliases for Dysentery:

Name: Dysentery 12 44 15 17 70
Infectious Diarrhea 12 54 62

Classifications:



External Ids:

Disease Ontology 12 DOID:12384
ICD9CM 34 009.2
MeSH 44 D004403
SNOMED-CT 67 154268000
UMLS 70 C0013369

Summaries for Dysentery

PubMed Health : 62 About infectious diarrhea: Diarrhea is very common: In Germany, for instance, adults get it once a year on average, and it is even more common in children. It is usually caused by viruses, the most common of which are the highly contagious norovirus and rotavirus. Infectious diarrhea can also come from bacteria such as Salmonella or Campylobacter. In normal cases of diarrhea, you can usually just replace the fluids you lose and wait until the infection goes away. But more severe or longer lasting diarrhea needs to be treated because it can lead to the loss of dangerously high levels of fluid and salt, especially in young children and older people.

MalaCards based summary : Dysentery, also known as infectious diarrhea, is related to amebiasis and shigellosis, and has symptoms including diarrhea An important gene associated with Dysentery is ALB (Albumin), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Allograft rejection. The drugs Loperamide and Mebendazole have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and bone.

Disease Ontology : 12 An intestinal infectious disease that involves inflammation of the intestines, especially colon, due to chemical irritants, bacteria, protozoa, or parasitic worms, which results in severe diarrhea with passage of mucus and blood.

Wikipedia : 73 Dysentery is a type of gastroenteritis that results in diarrhea with blood. Other symptoms may include... more...

Related Diseases for Dysentery

Diseases related to Dysentery via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 807)
# Related Disease Score Top Affiliating Genes
1 amebiasis 32.5 TNF IL1B CXCL8 ALB
2 shigellosis 32.2 TNF IL1B CXCL8 ALB
3 parasitic ectoparasitic infectious disease 31.9 H2AC18 CCR6 ALB
4 diarrhea 31.2 TTR TNF IL6 IL1B IFNA2 CXCL8
5 typhoid fever 31.0 TNF IL6 IL1B IL1A CRP CCR6
6 enterocolitis 31.0 TNF IL6 CXCL8
7 keratoconjunctivitis 30.9 TNF IL6 CXCL8 ALB
8 colitis 30.8 TNF IL6 IL1B CXCL8 CCR6
9 salmonellosis 30.7 TNF IL6 IL1B CXCL8 CCR6 ALB
10 ulcerative colitis 30.6 TNF IL6 IL1B CXCL8 CRP CCR6
11 ascaris lumbricoides infection 30.6 IL6 IL1B CXCL8
12 gastroenteritis 30.6 TNF IL6 IL1B CXCL8 CRP ALB
13 scarlet fever 30.6 TNF CRP ALB
14 acute diarrhea 30.5 STX2 STX1A ST8SIA2
15 lactose intolerance 30.5 CRP ATP12A ALB
16 sleeping sickness 30.4 TF IL6 HP H2AC18
17 intussusception 30.4 IL6 CRP ALB
18 tetanus 30.4 TNF IL6 IL1B IL1A CRP ALB
19 irritable bowel syndrome 30.3 TNF IL6 IL1B CXCL8 CRP
20 disseminated intravascular coagulation 30.3 TNF IL6 CRP
21 disease by infectious agent 30.3 TNF IL6 IL1B HP H2AC18 CRP
22 conjunctivitis 30.3 TNF IL6 CXCL8
23 appendicitis 30.3 TNF IL6 IL1B ENO2 CXCL8 CRP
24 paratyphoid fever 30.3 TNF IL1B IL1A CRP CCR6
25 guillain-barre syndrome 30.3 TNF HP ALB
26 viral hepatitis 30.2 TNF IL6 IL1B IFNA2 CRP ALB
27 toxic megacolon 30.2 TNF CRP CCR6 ATP12A ALB
28 gastritis 30.2 TNF IL6 IL1B CXCL8 CCR6
29 abdominal tuberculosis 30.2 TNF CRP ALB
30 pleural empyema 30.2 IL6 CRP ALB
31 splenic abscess 30.2 CRP ATP12A ALB
32 spondylosis 30.2 IL1B ENO2 CRP
33 plague 30.2 TNF IL6 IL1B H2AC18 ALB
34 peritonitis 30.2 TNF IL6 IL1B CXCL8 CRP ALB
35 enthesopathy 30.2 TNF CRP CCR6
36 drug allergy 30.2 CRP ATP12A ALB
37 autonomic nervous system disease 30.1 TTR IL6 ALB
38 brucellosis 30.1 TNF IL6 CXCL8 CRP
39 uremia 30.1 TNF IL6 CRP ALB
40 syphilis 30.1 TNF IL6 CRP CCR6 ALB
41 meningitis 30.1 TNF IL6 IL1B IL1A CXCL8 CRP
42 toxic shock syndrome 30.1 TNF IL6 IL1B CXCL8 CRP
43 cystitis 30.1 TNF IL6 IL1A CXCL8 CRP
44 graft-versus-host disease 30.1 TNF IL6 IL1B IL1A
45 duodenal ulcer 30.0 TNF IL6 IL1B CXCL8
46 infective endocarditis 30.0 TNF IL6 CRP
47 hepatitis a 30.0 TNF IL1B ALB
48 pasteurellosis 30.0 TNF HP CXCL8 ALB
49 pneumonia 30.0 TNF IL6 IL1B CXCL8 CRP ALB
50 iron deficiency anemia 30.0 TNF TF IL6 CRP

Comorbidity relations with Dysentery via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Dysentery:



Diseases related to Dysentery

Symptoms & Phenotypes for Dysentery

UMLS symptoms related to Dysentery:


diarrhea

Drugs & Therapeutics for Dysentery

PubMed Health treatment related to Dysentery: 62

You lose fluids and electrolytes when you have diarrhea , so it is important to replace them. For acute , non-severe diarrhea you usually just need something like tea with sugar and some salted crackers. Foods that are gentle on the stomach is recommended too, such as rice, bananas or rusk bread. Some people also avoid coffee, fruit juices, sodas, alcohol and fatty foods to keep from irritating their bowel even more. Acute , non-severe diarrhea does not require special treatment in adults and teenagers. But it is a good idea for young children and older people, as well as people with more severe diarrhea, to replace fluids and electrolytes by using oral rehydration salts (electrolyte /glucose solutions) from the pharmacy. These are powders containing salts, minerals and glucose that can be dissolved in water. If these solutions are not available (for instance, while traveling) the following ingredients can be stirred into one liter of bottled or boiled water: Five tablespoons of sugar One and a half level tablespoons of salt One glass of packaged orange juice In addition to drinking fluids and using other treatments , foods or dietary supplements that have probiotic microorganisms (probiotics ) in them can help to make the diarrhea go away faster. Depending on how severe the symptoms are and how long they last, other treatments may be considered too: Drugs like loperamide or racecadotril can help to slow down the activity of the bowel and lower the number of times you need to go to the bathroom. Loperamide is not suitable for children under the age of twelve years, and racecadotril is prescription-only for children. Sometimes certain types of yeast tablets (Perenterol) are also recommended. These tablets are thought to help the body get rid of the germs faster and to support natural gut flora. Charcoal tablets dissolved in water can also be taken to relieve diarrhea symptoms. But there is a lack of good-quality research in this area so no conclusions can be drawn about the benefits and harms of these treatment options. Antibiotics are only an option if the infection is bacterial. They can't fight viruses .

Drugs for Dysentery (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Loperamide Approved Phase 4 53179-11-6 3955
2
Mebendazole Approved, Vet_approved Phase 4 31431-39-7 4030
3
Piperazine Approved, Vet_approved Phase 4 110-85-0 4837
4
Sodium citrate Approved, Investigational Phase 4 68-04-2
5
Azithromycin Approved Phase 4 83905-01-5 55185 447043
6
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
7
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
8 Antidiarrheals Phase 4
9 Tubulin Modulators Phase 4
10 Antiparasitic Agents Phase 4
11 Citrate Phase 4
12 Antimitotic Agents Phase 4
13 DMP 777 Phase 4 157341-41-8
14 Anthelmintics Phase 4
15 Piperazine citrate Phase 4
16 Cytochrome P-450 Enzyme Inhibitors Phase 4
17 Anti-Retroviral Agents Phase 4
18 Fluoroquinolones Phase 4
19
Nitazoxanide Approved, Investigational, Vet_approved Phase 3 55981-09-4 41684
20
Zinc Approved, Investigational Phase 3 7440-66-6 32051
21 Antibiotics, Antitubercular Phase 2, Phase 3
22 Immunoglobulins Phase 3
23 Antibodies Phase 3
24 Trace Elements Phase 3
25 Nutrients Phase 3
26 Micronutrients Phase 3
27
Vancomycin Approved Phase 2 1404-90-6 441141 14969
28
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
29
Auranofin Approved, Investigational Phase 2 34031-32-8 6333901 6918453
30
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
31
Inulin Approved, Investigational, Nutraceutical Phase 1, Phase 2 9005-80-5 24763
32
Butyric Acid Experimental, Investigational Phase 2 107-92-6 264
33 Vaccines Phase 2
34 Acidophilus Phase 1, Phase 2
35 Complement System Proteins Phase 1, Phase 2
36 Immunosuppressive Agents Phase 1, Phase 2
37 Complement Factor H Phase 1, Phase 2
38 Neurotransmitter Agents Phase 2
39 Histamine Antagonists Phase 2
40
Histamine Phosphate Phase 2 51-74-1 65513
41 Immunologic Factors Phase 2
42 Adjuvants, Immunologic Phase 2
43 Antacids Phase 2
44 Anti-Ulcer Agents Phase 2
45 Antirheumatic Agents Phase 2
46 Rifamycins Phase 2
47 rifamycin SV Phase 2
48 Pharmaceutical Solutions Phase 2
49
Isoleucine Investigational, Nutraceutical Phase 2 73-32-5 6306
50
Aluminum sulfate Approved Phase 1 10043-01-3

Interventional clinical trials:

(show top 50) (show all 84)
# Name Status NCT ID Phase Drugs
1 Introduction of New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Management of Diarrhoeal Diseases - A Phase IV Surveillance Study Completed NCT00490932 Phase 4 Hypo-osmolar ORS
2 Rifaximin in Standard Three-Day Dosing With and Without the Antimotility Drug, Loperamide, in the Treatment of Travelers' Diarrhea Completed NCT00292344 Phase 4 Rifaximin and loperamide
3 Double-Blind, Placebo-Controlled, Randomized, Prospective, Two-Stage, Two-Arm Study to Evaluate the Efficaciousness and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population Completed NCT02385058 Phase 4 Mebendazole;Quinfamide;Placebo
4 A Phase 4 Open Label Study to Assess the Safety and Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in People Living With HIV/AIDS (PLWHA) With Non-Infectious Diarrhea Recruiting NCT04192487 Phase 4 Crofelemer delayed-release tablets 125mg
5 An Open Label Randomised Controlled Trial of Azithromycin Versus Ciprofloxacin for the Treatment of Children Hospitalised With Dysentery in Ho Chi Minh City, Vietnam Recruiting NCT03854929 Phase 4 Ciprofloxacin;Azithromycin
6 A Parallel, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Probiotic Formula in the Prevention of Traveler's Diarrhea Terminated NCT01005849 Phase 4
7 Single Daily Dose Rifaximin vs. Standard Thrice Daily Dosing for the 3-Day Treatment of Travelers' Diarrhea Withdrawn NCT00875875 Phase 4 Rifaximin
8 Double Blind, Placebo-Controlled Trial Assessing the Efficacy of Rifaximin in Preventing Campylobacteriosis in Subjects Challenged With Campylobacter Jejuni Completed NCT02280044 Phase 2, Phase 3
9 A Phase Three, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System Completed NCT00993681 Phase 3
10 A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy and Safety of Oral Daily Rifamycin SV-MMX® 400 mg b.i.d. vs. Ciprofloxacin 500 mg b.i.d. in the Treatment of Acute Infectious Diarrhoea in Travellers Completed NCT01208922 Phase 3 Rifamycin SV-MMX®;Ciprofloxacin
11 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rifamycin SV MMX for the Treatment of Traveler's Diarrhea Completed NCT01142089 Phase 3 Placebo;Rifamycin SV MMX
12 Phase 3 Study (Safety, Immunogenicity and Efficacy) of Improved Shigella Conjugate Vaccines in 1-4 Year Olds in Israel Completed NCT00368316 Phase 3
13 Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Tablets in the Treatment of Diarrhea Caused by Entamoeba Histolytica in Adults and Adolescents Completed NCT00366236 Phase 3 Nitazoxanide
14 Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Entamoeba Histolytica in Children Completed NCT00366730 Phase 3 Nitazoxanide
15 Effect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following recoveryEffect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following Recovery Completed NCT00321126 Phase 3 Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.
16 A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center, Therapeutic Equivalence Study to Compare Rifaximin 200 mg Tablets (Sandoz GmbH) to Xifaxan® 200 mg Tablets (Salix Pharmaceuticals, Inc.) and Placebo in Patients With Travelers' Diarrhea Terminated NCT02920242 Phase 3 Rifaximin (Sandoz GmbH) tablet;Rifaximin (Xifaxan);Placebo
17 Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea Withdrawn NCT02736539 Phase 3 CBS 2004 (galacto-oligosaccharides);Placebo
18 A Randomized, Double-Blind Study of GT160-246 Versus Vancomycin in Patients With C. Difficile-Associated Diarrhea Completed NCT00034294 Phase 2 GT160-246
19 Probiotics for Infectious Diarrhea in Children in South India Completed NCT01130792 Phase 1, Phase 2
20 Efficacy, Safety and Immunogenicity of GVGH Shigella Sonnei Vaccine (1790GAHB) in a Human Challenge Study of Healthy Non-immune Adults Completed NCT03527173 Phase 2 Placebo
21 Safety, Immunogenicity, and Efficacy Studies of WRSS1, a Live Attenuated Shigella Sonnei Vaccine Candidate, in Healthy Thai Adults Completed NCT01080716 Phase 1, Phase 2
22 A Phase Two, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System in Travelers to Asia Completed NCT01040325 Phase 2
23 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Two Vaccination Regimen With an LT Vaccine Patch in Healthy Adults Completed NCT00751777 Phase 2
24 Exploratory Study to Evaluate the Effect of L-isoleucine Supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children and in Inducing Innate Immunity Completed NCT01034228 Phase 2
25 Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea. A Pilot, Dose Finding, Double-blind, Randomized, Multicentre Study Completed NCT03447821 Phase 2 400 mg Rifamycin SV dosage;800 mg Rifamycin SV dosage;1200 mg Rifamycin SV dosage
26 Therapeutic Induction of Endogenous Antibiotics for Improved Recovery in Shigellosis Completed NCT00800930 Phase 2
27 Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection Completed NCT00485134 Phase 1, Phase 2
28 Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a Completed NCT02646371 Phase 2
29 A Phase 2a, Observer Blind, Randomized, Controlled, Single Center Study To Evaluate The Safety, Reactogenicity And Immunogenicity Of 2 Doses Of The GVGH 1790GAHB Vaccine Against Shigella Sonnei, Administered Intramuscularly In Adult Subjects From A Country Endemic For Shigellosis Completed NCT02676895 Phase 2
30 A Comparative Double Blind Placebo-Controlled Study of Immunogenicity and Safety of Two Doses 10^5 and 10^7 CFU of SC599 Oral Vaccine, a Live Attenuated Shigella Dysenteriae 1 Vaccine Strain in Healthy Human Adult Volunteers Completed NCT00210288 Phase 2
31 Phase IIa Randomized, Single-Blinded, Placebo-Controlled Clinical Trial of the Reprofiled Drug Auranofin for GI Protozoa Recruiting NCT02736968 Phase 2 Auranofin
32 Phase 2b Study of the Safety, Immunogenicity, and Efficacy of a Monovalent Synthetic Carbohydrate-based Conjugate Vaccine (SF2a-TT15) for Protection Against Shigella Flexneri 2a Experimental Infection Recruiting NCT04078022 Phase 2
33 Safety and Immunogenicity of a Shigella-Tetravalent Bioconjugate Vaccine: A Phase 1/2 Randomized Controlled and Age Descending Study Including Dose Finding in 9 Month Old Infants Recruiting NCT04056117 Phase 1, Phase 2
34 A Phase 2a Age Descending Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a in Adults, Children, and Infant Target Population in Endemic Countries. Recruiting NCT04602975 Phase 2
35 Double Blind, Multi-center Study to Evaluate the Safety and Efficacy of 100 mg Twice Daily Rifamycin SV MMX® Added to Standard ORT Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years Not yet recruiting NCT04026984 Phase 2 Rifamycin SV-MMX;Placebo
36 Double Blind Study to Evaluate the Safety and Efficacy of 400 mg Twice Daily Rifamycin SV MMX® Added to Standard Oral Rehydration Therapy (ORT) Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 12 to 17 Years Not yet recruiting NCT04027894 Phase 2 Rifamycin SV MMX;Placebo to Rifamycin SV-MMX
37 A Double-Blind Placebo Controlled Phase 2 Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of a Live-Attenuated Shigella Sonnei Vaccine, WRSs2 and Determine Its Efficacy in a Challenge Model of S. Sonnei 53G in Healthy Adults Not yet recruiting NCT04242264 Phase 2
38 Safety, Immunogenicity, and Efficacy Following Experimental Challenge of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set Shigella Flexneri 2a Live, Oral Vaccine: Phase IIa Vaccination Study Terminated NCT00866476 Phase 2
39 Safety, Immunogenicity, and Efficacy Following Experimental Challenge of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set Shigella Flexneri 2a Live, Oral Vaccine: Phase IIb Challenge Study Terminated NCT00866242 Phase 2
40 A Phase 2a/2b, Randomized, Double-blinded, Placebo-controlled, Trial to Assess the Safety, Immunogenicity and Efficacy of Inactivated Shigella Flexneri 2a Whole Cell (Sf2aWC) Vaccine Administered With and Without Double Mutant E. Coli Heat Labile Toxin (dmLT) in Healthy Adult Subjects Withdrawn NCT03038243 Phase 2
41 A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Oral Inactivated Whole Cell Shigella Flexneri 2a Vaccine in Healthy Adult Subjects Completed NCT01509846 Phase 1
42 A Phase 1 Open-label, Dose Escalating Study of Artificial Shigella Flexneri 2a InvaplexAR Administered Intranasally to Healthy, Adult Volunteers to Evaluate Safety and Immunogenicity Completed NCT02445963 Phase 1
43 A Phase I Dose Escalation Study to Assess the Safety and Immunogenicity of the SF2a-TT15 Conjugate Vaccine Against S. Flexneri 2a in Healthy Adult Volunteers Completed NCT02797236 Phase 1
44 A Single-center, Open, Phase I Clinical Trial to Evaluate Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months Completed NCT03561181 Phase 1
45 A Phase 1, Open Label, Non-randomized, Single Center Study to Evaluate the Safety and Immunogenicity of 1 Booster Vaccination With (GVGH Shigella Sonnei 1790GAHB) Vaccine Administered Intramuscularly in Healthy Adults Previously Primed With Three Doses of the Same Vaccine in Study H03_01TP Compared to 1 Vaccination With (1790GAHB) Administered Intramuscularly Either to Subjects Who Received Placebo in the H03_01TP Study or naïve Subjects Who Were Not Part of H03_01TP Study Completed NCT03089879 Phase 1
46 Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain Completed NCT02816346 Phase 1
47 Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3 Completed NCT01336699 Phase 1
48 Shigella Sonnel O-SPC/rBRU Conjugate Vaccine Completed NCT01369927 Phase 1
49 Safety, Clinical Tolerance, and Immunogenicity of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set, Live, Oral Shigella Flexneri 2a Vaccine Manufactured Using cGMP Completed NCT01531530 Phase 1
50 Safety and Reactogenicity of a Candidate Vaccine Against S. Dysenteriae When Administered to Healthy Adults Completed NCT01069471 Phase 1

Search NIH Clinical Center for Dysentery

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Ciprofloxacin
Scopolamine
Scopolamine Hydrobromide

Cochrane evidence based reviews: dysentery

Genetic Tests for Dysentery

Anatomical Context for Dysentery

MalaCards organs/tissues related to Dysentery:

40
Liver, Colon, Bone, Skin, Heart, Kidney, Small Intestine

Publications for Dysentery

Articles related to Dysentery:

(show top 50) (show all 8469)
# Title Authors PMID Year
1
Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. 54 61
19028207 2008
2
Antibiotics for the empirical treatment of acute infectious diarrhea in children. 61 54
17568855 2006
3
Bioaccumulation of Organochlorine Pesticides, Procamallanus sp. (Baylis, 1923) infections, and Microbial Colonization in African Snakehead fish Sampled from Lekki Lagoon, Lagos, Nigeria. 61
33053141 2021
4
Tectona grandis leaf extract ameliorates hepatic fibrosis: Modulation of TGF- β /Smad signaling pathway and upregulating MMP3/TIMP1 ratio. 61
33610708 2021
5
Syzygium cumini(L.),Skeels fruit extracts: In vitro and in vivo anti-inflammatory properties. 61
33465442 2021
6
The protective effects of Ziziphora tenuior L. against chlorpyrifos induced toxicity: Involvement of inflammatory and cell death signaling pathway. 61
33636318 2021
7
Gegen Qinlian decoction relieved DSS-induced ulcerative colitis in mice by modulating Th17/Treg cell homeostasis via suppressing IL-6/JAK2/STAT3 signaling. 61
33640781 2021
8
Euphorbia helioscopia L.: A phytochemical and pharmacological overview. 61
33440297 2021
9
The direct and interactive impacts of hydrological factors on bacillary dysentery across different geographical regions in central China. 61
33385650 2021
10
A Millifluidic Perfusion Cassette for Studying the Pathogenesis of Enteric Infections Using Ex-Vivo Organoids. 61
33409849 2021
11
Heat-stable enterotoxin inhibits intestinal stem cell expansion to disrupt the intestinal integrity by downregulating the Wnt/β-catenin pathway. 61
33373490 2021
12
Traditional uses, phytochemistry, pharmacology, and toxicology of Coreopsis tinctoria Nutt.: A review. 61
33309917 2021
13
EP3: an ensemble predictor that accurately identifies type III secreted effectors. 61
32043137 2021
14
Gastroprotective activity of kaempferol glycosides from Malvaviscus arboreus Cav. 61
33253829 2021
15
Enteral myiasis causing acute dysentery: A case report. 61
33797537 2021
16
Interleukin-33 signaling exacerbates experimental infectious colitis by enhancing gut permeability and inhibiting protective Th17 immunity. 61
33654214 2021
17
Slc26a3 (DRA) in the Gut: Expression, Function, Regulation, Role in Infectious Diarrhea and Inflammatory Bowel Disease. 61
32989468 2021
18
Host genome wide association study of infant susceptibility to Shigella-associated diarrhea. 61
33649051 2021
19
Alteration of Colonic Mucin Composition and Cytokine Expression in Acute Swine Dysentery. 61
33686884 2021
20
Association between floods and the risk of dysentery in China: a meta-analysis. 61
33660029 2021
21
Real-time forecasting and early warning of bacillary dysentery activity in four meteorological and geographic divisions in China. 61
33360132 2021
22
Virulence Profiles of Diarrheagenic Escherichia coli Isolated from the Western Region of Ghana. 61
32863350 2021
23
Quinolone resistant Salmonella species isolated from pediatric patients with diarrhea in central Iran. 61
33784974 2021
24
Effects of Bovine Colostrum with or without Egg on In Vitro Bacterial-Induced Intestinal Damage with Relevance for SIBO and Infectious Diarrhea. 61
33809940 2021
25
Effect of ambient temperatures on category C notifiable infectious diarrhea in China: An analysis of national surveillance data. 61
33198999 2021
26
Target Product Profile and Development Path for Shigellosis Treatment with Antibacterials. 61
33689318 2021
27
Entamoeba histolytica-Gut Microbiota Interaction: More Than Meets the Eye. 61
33809056 2021
28
Large metabolic rewiring from small genomic changes between strains of Shigella flexneri. 61
33753469 2021
29
Study on the mechanism of active components of Liupao tea on 3CLpro based on HPLC-DAD fingerprint and molecular docking technique. 61
33760271 2021
30
Role of anthraquinones in Cassia occidentalis induced hepato-myo-encephalopathy. 61
33011371 2021
31
Loss of the virulence plasmid by Shigella sonnei promotes its interactions with CD207 and CD209 receptors. 61
33591245 2021
32
New lathyrane diterpenoids with anti-inflammatory activity isolated from the roots of Jatropha curcas L. 61
33301921 2021
33
An in-vitro study on a novel six-phage cocktail against multi-drug resistant-ESBL Shigella in aquatic environment. 61
33070360 2021
34
Queuine Is a Nutritional Regulator of Entamoeba histolytica Response to Oxidative Stress and a Virulence Attenuator. 61
33688012 2021
35
Two chromones with antimicrobial activity from the leaf latex of Aloe monticola Reynolds. 61
31137974 2021
36
Colonization with Gastrointestinal Pathogens Prior to Hematopoietic Cell Transplantation and Associated Clinical Implications. 61
33811020 2021
37
Review of zoonotic amebiasis: Epidemiology, clinical signs, diagnosis, treatment, prevention and control. 61
33676155 2021
38
Exploration of the relationship between intestinal flora changes and gut acute graft-versus-host disease after hematopoietic stem cell transplantation. 61
33708514 2021
39
Protection against severe infectious disease in the past. 61
33573529 2021
40
Tiaochang Xiaoyan extract tablets ameliorate chronic inflammation by activating macrophage lysosomes in chronic colitis rats. 61
33725775 2021
41
Bacterial Infections in Cirrhotic Patients in a Tertiary Care Hospital. 61
33604253 2021
42
Highly Fermentable Fiber Alters Fecal Microbiota and Mitigates Swine Dysentery Induced by Brachyspira hyodysenteriae. 61
33557345 2021
43
[Spatio-temporal dynamics of bacillary dysentery outbreaks in Democratic Republic of the Congo, 1999-2013]. 61
33518368 2021
44
Dysentery as the only presentation of COVID-19 in a child: a case report. 61
33557906 2021
45
Spatiotemporal variations in the incidence of bacillary dysentery and long-term effects associated with meteorological and socioeconomic factors in China from 2013 to 2017. 61
33039932 2021
46
Contribution of noncanonical antigens to virulence and adaptive immunity in human infection with enterotoxigenic E. coli. 61
33558320 2021
47
Lubeluzole: from anti-ischemic drug to preclinical antidiarrheal studies. 61
33074530 2021
48
Traditional uses and pharmacological activities of the genus leea and its phytochemicals: A review. 61
33659746 2021
49
Recent phytochemical and pharmacological advances in the genus Potentilla L. sensu lato - An update covering the period from 2009 to 2020. 61
32987127 2021
50
Antimicrobial susceptibility of bacterial isolates from the conjunctiva, storage cases and mobile phones of university students using contact lenses. 61
31722813 2021

Variations for Dysentery

Expression for Dysentery

Search GEO for disease gene expression data for Dysentery.

Pathways for Dysentery

Pathways related to Dysentery according to GeneCards Suite gene sharing:

(show all 45)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.35 TNF STX1A IL6 IL1B IL1A IFNA2
2
Show member pathways
12.86 TNF IL6 IL1B IL1A IFNA2 CXCL8
3
Show member pathways
12.83 TNF IL6 IL1B IL1A IFNA2 CXCL8
4
Show member pathways
12.43 TNF IL6 IL1B IFNA2 CXCL8
5
Show member pathways
12.34 TNF IL6 IL1B CRP ALB
6
Show member pathways
12.33 TNF IL6 IL1B IL1A CXCL8
7
Show member pathways
12.32 TNF IL6 IL1B CXCL8
8
Show member pathways
12.32 TNF IL6 CXCL8 CCR6
9
Show member pathways
12.26 TNF IL6 IL1A CXCL8
10 12.25 TNF IL6 IL1B IFNA2 CXCL8
11 12.24 TNF IL6 IL1B IL1A IFNA2
12
Show member pathways
12.24 TNF IL6 IL1B IL1A IFNA2 CXCL8
13
Show member pathways
12.22 TNF IL6 IL1B IL1A CXCL8
14
Show member pathways
12.2 TNF IL1B IL1A IFNA2 H2AC18
15
Show member pathways
12.19 TNF IL6 IL1B CXCL8
16 12.1 TNF IL6 IL1B CXCL8
17 11.97 TNF IL6 IL1B IL1A CXCL8
18 11.95 IL6 IL1B IL1A CXCL8
19 11.94 TNF TF IL6 IL1B IL1A CXCL8
20 11.93 TNF IL6 IL1B CXCL8
21 11.93 TNF IL6 IL1B IL1A CXCL8
22 11.91 TNF IL6 IL1B IL1A
23 11.83 TNF IL6 IL1B IL1A CXCL8
24 11.77 TNF IL1B CCR6
25 11.77 TNF IL6 IL1B IFNA2
26 11.77 TNF IL6 IL1B IL1A CXCL8
27
Show member pathways
11.75 TNF IL6 IL1B
28 11.68 TNF IL6 CCR6
29 11.65 TNF IL6 IL1B CXCL8
30 11.6 TNF IL6 IL1B IL1A CXCL8
31 11.59 TNF IL6 IL1B CXCL8
32 11.53 IL6 IL1B IL1A
33 11.52 TNF IL6 HP
34 11.52 TNF IL6 IL1B CXCL8
35
Show member pathways
11.47 TNF STX1A IL1B
36 11.46 TNF IL6 IL1B IL1A
37 11.4 TNF IL6 IL1B
38 11.33 TNF IL6 IL1B
39 11.31 TNF IL6 IL1B
40 11.3 TNF IL6 IL1B IL1A
41
Show member pathways
11.15 TNF IL6 IL1B IL1A CXCL8
42 11.13 TNF IL6 IL1B IL1A
43 10.74 TNF IL6 CXCL8 CRP
44 10.71 TNF IL6 IL1B IL1A CXCL8
45 10.52 IL1B IL1A

GO Terms for Dysentery

Cellular components related to Dysentery according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 TTR TNF TF STX1A IL6 IL1B
2 extracellular space GO:0005615 9.44 TTR TNF TF STX2 IL6 IL1B

Biological processes related to Dysentery according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.01 TNF IL6 IL1B IL1A CXCL8 CRP
2 immune response GO:0006955 10 TNF IL6 IL1B IL1A CXCL8 CCR6
3 cellular protein metabolic process GO:0044267 9.92 TTR TF IL6 ALB
4 defense response GO:0006952 9.9 TNF IFNA2 HP CXCL8
5 cellular response to lipopolysaccharide GO:0071222 9.8 TNF IL6 IL1B IL1A CXCL8
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.79 TNF IL6 IFNA2
7 positive regulation of interleukin-8 production GO:0032757 9.79 TNF IL6 IL1B
8 positive regulation of interleukin-6 production GO:0032755 9.78 TNF IL6 IL1B IL1A
9 acute-phase response GO:0006953 9.75 IL6 HP CRP
10 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.74 TNF IL1B IL1A
11 regulation of insulin secretion GO:0050796 9.73 TNF STX1A IL6 IL1B
12 positive regulation of vascular endothelial growth factor production GO:0010575 9.69 IL6 IL1B IL1A
13 negative regulation of neurogenesis GO:0050768 9.67 TNF IL6 IL1B
14 regulation of establishment of endothelial barrier GO:1903140 9.63 TNF IL1B
15 positive regulation of glial cell proliferation GO:0060252 9.63 TNF IL6 IL1B
16 humoral immune response GO:0006959 9.62 TNF IL6 IFNA2 CCR6
17 positive regulation of fever generation GO:0031622 9.61 TNF IL1B
18 positive regulation of immature T cell proliferation in thymus GO:0033092 9.59 IL1B IL1A
19 sequestering of triglyceride GO:0030730 9.58 TNF IL1B
20 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.56 TNF IL1B
21 fever generation GO:0001660 9.55 IL1B IL1A
22 positive regulation of neuroinflammatory response GO:0150078 9.54 TNF IL6 IL1B
23 inflammatory response GO:0006954 9.5 TNF IL6 IL1B IL1A IFNA2 CXCL8
24 negative regulation of lipid storage GO:0010888 9.43 TNF IL6 CRP
25 vascular endothelial growth factor production GO:0010573 9.33 TNF IL6 IL1B
26 cytokine-mediated signaling pathway GO:0019221 9.23 TNF STX1A IL6 IL1RAPL2 IL1B IL1A

Molecular functions related to Dysentery according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.1 TNF IL6 IL1B IL1A IFNA2 CXCL8

Sources for Dysentery

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....